J&J wants to be the leader in the cancer fight. Its strategy is starting to pay off as oncology sales top $25 billion in 2025.

BIAS: Center
RELIABILITY: Mixed
MarketWatch
15:14Z

Johnson & Johnson sees revenue grow 9% in the fourth quarter, amid strength in its cancer drugs.

Continue reading at the original source

Read Full Article at MarketWatch →